Altimmune, Inc. (ALT)
| Market Cap | 340.96M |
| Revenue (ttm) | 6.81M |
| Net Income (ttm) | -60.02M |
| Shares Out | 38.91M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $8.88 |
| Previous Close | $9.25 |
| Change ($) | -0.37 |
| Change (%) | -4.00% |
| Day's Open | 9.26 |
| Day's Range | 8.84 - 9.29 |
| Day's Volume | 737,864 |
| 52-Week Range | 7.80 - 29.71 |
Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.
The company halts development on both a COVID-19 vaccine and a drug targeting the disease.
Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the development ...
Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 1/2 trial for T-COVID, single-d...
The following stocks are attracting high retail-investor interest on social media early Wednesday. SoFi Technologies Inc (NASDAQ:SOFI): The personal finance company continues to dominate r/WallStreetBe...
GAITHERSBURG, Md., June 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the pr...
Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...
Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was a...
An experimental new weight loss drug produced compelling data in an early stage clinical trial.
Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study is currently being condu...
GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its...
Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine neutralized the COVID-19 B.1.351 variant th...
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June
GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial result...
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The resul...
Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alternus Energy Group PLC (NOTC:ALT) named industry veteran Gary Swan as its chief technical officer, as the fast-growing independent power producer expands its footprint across Europe. “Swan will join...
Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, announced the recent issuance of €9 million convertible notes lead by AVG Group Sarl, a Luxembourg-based a...
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...
The short answer: It depends.
Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose...
GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine...
Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, has announced the completion of the acquisition of two additional solar parks in Romania from Renesola Pow...
Metered Multidose Device Allows for Convenient and Cost-effective Vaccination Metered Multidose Device Allows for Convenient and Cost-effective Vaccination
If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.
Altimmune Inc. (NASDAQ: ALT) is making headway in the fight against COVID-19 after the firm announced additional preclinical data in regards to its single-dose intranasal vaccine candidate, AdCOVID.
Altimmune Inc (NASDAQ: ALT) has reported additional preclinical data for COVID-19 vaccine candidate, AdCOVID. The data showed that a single intranasal dose of AdCOVID provided 100% protection against th...
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...
Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under t...
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commerci...
Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...
Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a...
Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is particul...
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results o...
The company's COVID-19 program is moving ahead.
Altimmune Inc (NASDAQ: ALT) shares are advancing following an update on its coronavirus vaccine program. What Happened: Maryland-based Altimmune said the FDA has cleared its investigational new drug app...
Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free, ...
No kidding around ... here's how they truly can.
New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are ad...
Transport and storage of their potential vaccines would be a piece of cake.
This biotech just might have what it takes.
They're risky but could deliver huge returns in the new year.
Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune...
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that i... [Read more...]
| Industry Biotechnology | |
| CEO Vipin Garg | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol ALT |
Financial Performance
In 2020, Altimmune's revenue was $8.19 million, an increase of 41.09% compared to the previous year's $5.80 million. Losses were -$49.04 million, 139.0% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 24.86, which is an increase of 179.95% from the latest price.